ATEMPT study shows that 5 years after treatment, 97% of patient's w/stage 1 HER2+ breast cancer treated w/TDM1 were alive and free from invasive disease and 98.3% had no recurrence of their cancer.
Advertisement
Recommendations
Advertisement